Diether based biodegradable cationic lipids for siRNA delivery
Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.
1. A cationic lipid of Formula A:
wherein:
R 1 and R 2 are independently selected from H, (C 1 -C 6 )alkyl, heterocyclyl, and polyamine, wherein said alkyl, heterocyclyl and polyamine are optionally substituted with one to three substituents selected from R 1 ; or R 1 and R 2 can be taken together with the nitrogen to which they are attached to form a monocyclic heterocycle with 4-7 members optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic heterocycle is optionally substituted with one to three substituents selected from R′;
R 5 is independently selected from (C 4 -C 8 )alkylene or (C 4 -C 8 )alkenylene, said alkylene or alkenylene optionally substituted with one to three substituents selected from R′;
R 6 is (C 1 -C 2 )alkyl, said alkyl optionally substituted with one to three substituents selected from R′;
Q 2 is a bond, —OC(O)—, —C(O)O—, —SC(O)—, —C(O)S—, —OC(S)—, —S—S, —C(R″)═N—, —N═C(R″)—, —C(R″)═N—O—, —O—N═C(R″)—, —C(O)(NR″)—, —N(R″)C(O)—, —C(S)(R″)—, —(R″)C(O)—, —N(R″)C(O)N(R″)—, —OC(O)O—, OSi(R″) 2 O—, —C(O)(CR″ 2 )C(O)O—, or —OC(O)(CR″ 2 )C(O)—, with the proviso that when either Q 1 or Q 2 is a bond then the other is not a bond;
each occurrence of R′ is independently selected from halogen, R″, OR″, SR″, CN, CO 2 R″ or CON(R″) 2 ;
R″ is independently selected from H and (C 1 -C 6 )alkyl, wherein said alkyl is optionally substituted with halogen and OH;
n is 0, 1, 2, 3, 4 or 5; and
-R 3 -Q 1 -R 4 is selected from the group consisting of
or a pharmaceutically acceptable salt or stereoisomer thereof.
2. A cationic lipid of claim 1 , wherein:
R 1 and R 2 are each methyl;
n is 0;
R 5 is independently selected from (C 4 -C 8 )alkylene and (C 4 -C 8 )alkenylene, said alkylene or alkenylene optionally substituted with one to three substituents selected from R′;
R 6 is (C 1 -C 2 )alkyl, said alkyl optionally substituted with one to three substituents selected from R′;
Q 2 is a bond or —C(O)O—;
or a pharmaceutically acceptable salt or stereoisomer thereof.
3. A lipid nanoparticle comprising a cationic lipid of claim 1 .
4. The lipid nanoparticle of claim 3 , wherein the lipid particle comprises oligonucleotides.
5. The lipid nanoparticle of claim 4 , wherein the oligonucleotides are siRNA.
6. A lipid nanoparticle comprising a cationic lipid of claim 1 cholesterol, DSPC and PEG-DMG.